COMBIVIR - 52959-546-02 - (lamivudine and zidovudine)

Alphabetical Index


Drug Information of COMBIVIR

Product NDC: 52959-546
Proprietary Name: COMBIVIR
Non Proprietary Name: lamivudine and zidovudine
Active Ingredient(s): 150; 300    mg/1; mg/1 & nbsp;   lamivudine and zidovudine
Administration Route(s): ORAL
Dosage Form(s): TABLET, FILM COATED
Coding System: National Drug Codes(NDC)

Labeler Information of COMBIVIR

Product NDC: 52959-546
Labeler Name: H.J. Harkins Company, Inc.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA020857
Marketing Category: NDA
Start Marketing Date: 20101019

Package Information of COMBIVIR

Package NDC: 52959-546-02
Package Description: 2 TABLET, FILM COATED in 1 BOTTLE (52959-546-02)

NDC Information of COMBIVIR

NDC Code 52959-546-02
Proprietary Name COMBIVIR
Package Description 2 TABLET, FILM COATED in 1 BOTTLE (52959-546-02)
Product NDC 52959-546
Product Type Name HUMAN PRESCRIPTION DRUG
Non Proprietary Name lamivudine and zidovudine
Dosage Form Name TABLET, FILM COATED
Route Name ORAL
Start Marketing Date 20101019
Marketing Category Name NDA
Labeler Name H.J. Harkins Company, Inc.
Substance Name LAMIVUDINE; ZIDOVUDINE
Strength Number 150; 300
Strength Unit mg/1; mg/1
Pharmaceutical Classes Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA]

Complete Information of COMBIVIR


General Information